Feasibility Aspects of Exploring Exercise-Induced Neuroplasticity in Parkinson’s Disease: A Pilot Randomized Controlled Trial

Table 2

Assessment schedule.

Outcome domain	Test	Preintervention sessions				Postintervention sessions
		I	II	III	Others	I	II	III	Others
Balance	Mini-BESTest	√				√
	ABC-scale	√				√
Gait	GAITRite® analysis	√				√
	Walk 12	√				√
Motor function	MDS-UPDRS part I-III	√				√
Physical activity	Accelerometer wear, 7 days				√				√
QoL and health status	EQ5D	√				√
	PDQ-39	√				√
	HADS	√				√
Global cognition	MoCA	√				√
Executive function	Trail making test, trial IV; the color-word interference test; verbal fluency		√				√
			√				√
			√				√
			√				√
Attention/working memory	Digit span; trail making test, trials I-III		√				√
			√				√
Episodic memory	Brief visuospatial memory test; brief visuospatial memory test-revised (BVMT-R)		√				√
Visuospatial functions	Copy condition from BVMT-R		√				√
Brain structure and function	Magnetic resonance imaging (MRI)			√				√
	Task functional MRI (fMRI)			√				√
	Resting state fMRI			√				√
Level of BDNF	Blood sample				√				√
Voice intensity	Speech recording		√				√
Dysarthria	Dysarthria assessment		√				√
Acceptability	MRI questionnaire			√
	Intervention follow-up questionnaire								√

Abbreviations: Mini-BESTest, Mini-Balance Evaluation Systems Test; ABC-scale, Activities-specific Balance Confidence scale; MDS-UPDRS, Movement Disorder Society–Unified Parkinsons Disease Rating Scale; EQ5D, EuroQol 5 dimensions; PDQ-39, Parkinsons Disease Questionnaire -39; HADS, Hospital Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment.